These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20394161)

  • 21. Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
    Galli M; Andreotti F; Savarese G; D'Amario D; Vergallo R; Della Bona R; Calò L; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):55-56. PubMed ID: 30289484
    [No Abstract]   [Full Text] [Related]  

  • 22. [Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)].
    Lengyel M
    Orv Hetil; 2005 Sep; 146(37):1937-8. PubMed ID: 16255379
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
    Kreutz RP; Stanek EJ; Aubert R; Yao J; Breall JA; Desta Z; Skaar TC; Teagarden JR; Frueh FW; Epstein RS; Flockhart DA
    Pharmacotherapy; 2010 Aug; 30(8):787-96. PubMed ID: 20653354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antithrombotic therapy in patients with atrial fibrillation: a comment on the European guidelines].
    Said SM; Nahrendorf W; Schmidt H; Braun-Dullaeus RC
    Dtsch Med Wochenschr; 2011 Jun; 136(25-26):1384-5. PubMed ID: 21674428
    [No Abstract]   [Full Text] [Related]  

  • 25. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
    Yasuda H; Yamada M; Sawada S; Endo Y; Inoue K; Asano F; Takeyama Y; Yoshiba M
    Intern Med; 2009; 48(19):1725-30. PubMed ID: 19797827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)].
    Gratsianskiĭ NA
    Kardiologiia; 2003; 43(5):71-3. PubMed ID: 12942928
    [No Abstract]   [Full Text] [Related]  

  • 27. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Meinertz T
    Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
    [No Abstract]   [Full Text] [Related]  

  • 28. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Manzano-Fernández S; Pastor FJ; Marín F; Cambronero F; Caro C; Pascual-Figal DA; Garrido IP; Pinar E; Valdés M; Lip GYH
    Chest; 2008 Sep; 134(3):559-567. PubMed ID: 18641090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
    Preobrazhenskiĭ DV; Sidorenko BA; Fettser DV; Batyraliev TA; Niiazova-Karben ZA; Besnili F
    Kardiologiia; 2010; 50(5):73-6. PubMed ID: 20831051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dilemma between gastroprotection and cardiovascular prevention].
    Venerito M; Kandulski A; Malfertheiner P
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2193-8. PubMed ID: 20979006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
    Jähne J; Schirren J
    Chirurg; 2009 Jun; 80(6):497. PubMed ID: 19434381
    [No Abstract]   [Full Text] [Related]  

  • 33. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
    Valgimigli M; Minarelli M
    Am Heart J; 2010 Dec; 160(6 Suppl):S36-41. PubMed ID: 21147290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
    Singh PP; Singh M; Bedi U; Molnar J; Arora R; Khosla S
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):23-31. PubMed ID: 21183532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    Lopes RD; Li L; Granger CB; Wang TY; Foody JM; Funk M; Peterson ED; Alexander KP
    Am J Med; 2012 Sep; 125(9):897-905. PubMed ID: 22795814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
    Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.
    Harjai KJ; Shenoy C; Orshaw P; Usmani S; Boura J; Mehta RH
    Circ Cardiovasc Interv; 2011 Apr; 4(2):162-70. PubMed ID: 21386091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.